← All organizations
Highest phase reached
Phase 4
First clinical trial
Nov 1, 2013Last known activity
Oct 31, 2024
Timeline
1950s
- Jan 1, 1958
Chengdu Institute of Biological Products Co.,Ltd.— Founded
Drugs by trial phase (13 distinct, 11 trials)
Phase 4 (10 own, 0 via acquisition)
- 23-valent pneumococcal polysaccharide vaccine
- tivantinib
- multi-valent pneumococcal conjugate vaccine
- inactivated influenza vaccine
- live oral poliovirus type 1, 2 and 3
- measles, mumps, and rubella vaccine
- acellular pertussis vaccine (including diptheria and tetanus toxoids)
- covax-19
- inactivated sabin strain polio virus
- Inactivated polio virus - Enhanced
Phase 3 (2 own, 0 via acquisition)
Phase 2 (1 own, 0 via acquisition)
Indications
Recent trials (11)
- NCT06632912CollaboratorPhase 3Oct 31, 2024
- NCT05480436CollaboratorPhase 4Aug 5, 2022
- NCT05262010CollaboratorPhase 3Jun 4, 2022
- NCT05079152CollaboratorPhase 4May 6, 2021
- NCT04790851CollaboratorPhase 4Mar 10, 2021
- NCT04638985CollaboratorPhase 4Nov 13, 2020
- NCT04559204CollaboratorPhase 4Sep 11, 2020
- NCT04436133CollaboratorPhase 2Jun 22, 2020
- NCT04083196CollaboratorPhase 1Sep 7, 2019
- NCT04054882CollaboratorPhase 4Aug 31, 2019
- NCT02062281CollaboratorPhase 4Nov 1, 2013
Details
- Founded
- Chengdu, CN Jan 1, 1958
- Last known activity
- Oct 31, 2024